China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
On September 27, 2024, Harbour BioMed filed a patent infringement lawsuit with the Shanghai Intellectual Property Court against Biocytogen, alleging that its RenNano platform infringes Harbour BioMed's HCAb Patent. Biocytogen subsequently challenged the court's jurisdiction, first through an objection submitted to the Shanghai Intellectual Property Court on November 8, 2024, and later through an appeal to the Supreme People's Court of the People's Republic of China on March 14, 2025. On May 27, 2025, the Supreme People's Court of the People's Republic of China issued a final ruling, dismissing the appeal and affirming the jurisdiction of the Shanghai Intellectual Property Court over the infringement lawsuit. This case has now advanced to the next stage of trial.
Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: 'CNIPA's decision affirms the rightful protections of the pioneering innovation and core value of Harbour BioMed's intellectual property. We have established a global patent portfolio across key markets, providing robust protection for R&D investments and proprietary innovations enabled by our Harbour Mice® platform and associated technologies. Moving forward, we will continue to leverage our patented HCAb technology to accelerate the development of transformative therapies in collaboration with global partners, ultimately bringing meaningful benefits to patients worldwide.'
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
a day ago
- The Star
Hong Kong's all-male boards are all but gone as firms embrace diversity
Hong Kong's bourse operator has declared victory in its quest to eliminate all-male boards from companies listed on the region's third-largest stock exchange, an improvement in corporate governance that analysts said would help attract international investors. Fewer than 10 of Hong Kong's around 2,600 listed companies had all-male boards as of the end of June, according to Hong Kong Exchanges and Clearing (HKEX). A spokesman said these exceptions were companies that had long been suspended from trading or were merely out of compliance temporarily because of a resignation. Eighty-five companies had all-male boards on January 1 when HKEX's ban on single-gender boards went into effect. In 2022, when the bourse operator unveiled the ban, more than 800 firms – or 40 per cent of listed companies – did not have a woman director. 'This requirement helped to create hundreds of new roles for female directors, reinforcing our commitment to fostering a more inclusive and diverse corporate environment and enhanced governance in our markets,' said Katherine Ng, HKEX's head of listing, in a statement to the Post. An example of a non-compliant company is property investment firm Paladin, which has six male board members. Its shares were suspended from trading in November because of insufficient business operations. To resume trading, the exchange would require a new business operation plan and at least one woman would need to join the board, the company said in February. More than 800 women had been added to listed companies' boards in the past four years, HKEX said. As of June, 21 per cent of directors were women, up from 20 per cent six months ago and 16 per cent four years ago when the single-gender ban was unveiled. The number of boards with multiple women increased to 43 per cent as of June from 35 per cent in 2022, and 21 per cent of listed companies now had boards where women accounted for a third of the directors. 'Ensuring more women on boards is a fundamental reform for listed companies anywhere, and it is confidence-building for investors to see HKEX taking definitive measures to move this along,' said Damien Green, a director of the Financial Services Development Council, a government agency that promotes the city as an international financial centre. Green cited the ban on all-male boards as a factor that helped the exchange's main board return to the top of the global league table for initial public offerings (IPOs) in the first half of the year. 'Strengthening corporate governance in the HKEX listing rules will not slow our market down but instead will help accelerate it, as international investors find yet another reason to have confidence in deploying their capital in Hong Kong,' he said. Funds from Hong Kong's IPOs soared eightfold to US$13.5 billion in the first six months, making the city's exchange the world's top IPO venue for the first time since 2019, according to data from the London Stock Exchange Group. Despite progress, Hong Kong-listed companies trail their global peers in gender diversity on their boards. Globally, 27 per cent of board seats among around 3,000 companies in the MSCI All Country World Index were occupied by women as of 2024, up 1.5 per cent from a year earlier, MSCI said in February. Edmund Wong, a lawmaker for the accountancy sector, said he supported HKEX in promoting gender diversity, but added that the ability of directors was also important and that women with relevant experience could be in short supply in certain sectors. 'Listed companies in the construction sector or engineering may not easily find a lot of women,' Wong said. -- SOUTH CHINA MORNING POST
Malaysian Reserve
a day ago
- Malaysian Reserve
Mowilex models environmental leadership with new Cikande factory solar panels: for every 4 liters of Mowilex paint, 1 is now powered by the sun
Key news highlights: With new solar panels at its Cikande factory, Mowilex has expanded its commitment to renewable energy, efficiency and the environment. The installation will lower the company's carbon footprint and cut grid electricity use by up to 25% per year. Mowilex earned its sixth consecutive CarbonNeutral® company certification in late 2024, and further supports Indonesia's clean energy goals with this solar project. JAKARTA, Indonesia, July 4, 2025 /PRNewswire/ — With the installation of solar panels at its Cikande factory, PT Mowilex Indonesia (Mowilex) is expanding its long-standing commitment to clean, renewable energy. Mowilex was Indonesia's first paint company to make major solar investments, demonstrating environmental leadership by first installing panels at its corporate headquarters in 2022. Over 500 solar modules now cover the roof of the main Cikande factory building. Another 252 solar modules were installed on car and motorcycle parking canopies. The system will reduce grid electricity use at the company's Cikande factory by approximately 500 kilowatt-hours (kWh) annually – and that means 1 of every 4 liters produced will be made with renewable energy. With the Cikande solar panels, Mowilex will lower its operational carbon footprint and cut non-renewable energy use by up to 25% per year. The company's new renewable energy project advances Indonesia's clean energy goals and comes just months after Mowilex earned its sixth consecutive CarbonNeutral® company certification. 'We believe in taking real action to decarbonize. This solar installation at our Cikande factory goes beyond buying offsets, and it's more than a technological upgrade. It is a reflection of our core values. As a company rooted in environmental responsibility, this initiative brings us one step closer to a cleaner future for Indonesia,' says Niko Safavi, CEO of PT Mowilex Indonesia. Through its investment in solar projects, Mowilex is actively reducing its dependence on brown energy. In contrast to brown energy, derived from fossil fuels and associated with high emissions and environmental harm, green energy represents a cleaner, renewable alternative. This strategic transition enables Mowilex to adopt a more stable, self-sufficient and environmentally responsible energy solution. The expanded use of solar also aligns with the environmental and ethical expectations of Indonesian consumers. Climate change worries 87% of Indonesians, says the global communications firm Edelman, and more than 90% of Indonesians think businesses don't do enough engagement around climate change issues. Another 90% expect CEOs to take a public stance on climate change. Mowilex embraces the opportunity to educate and deliver solutions to climate challenges through its products and practices. 'We see consumers shifting their purchasing power toward brands that actively work to mitigate climate change. Mowilex is proud to meet those market expectations,' says Safavi. 'Solar is a reliable, independent power source that contributes to our energy security and supports Indonesia's renewable energy policies. By making this long-term investment, we hope to be a model for industry and for the greater public.' Learn more about Mowilex sustainability programs and products at About PT Mowilex Indonesia PT Mowilex Indonesia (Mowilex), a subsidiary of Asia Coatings Enterprises, Pte. Ltd., is a leading producer of premium paints and coatings. Since launching the first Indonesian-made, water-based paints in 1970, the company has expanded its commitment to environmental ethics, equality, community and innovation. PT Mowilex is Indonesia's only certified carbon neutral manufacturer, producing zero and low VOC paints in modern colours, and the company regularly wins awards for its corporate social responsibility and sustainability efforts. Media contact: media@ Visit the Mowilex website for product and sustainability information.
The Sun
2 days ago
- The Sun
AweMed Series Sponsors Eczema Family Day 2025 to Support Singapore's Sensitive Skin Community
SINGAPORE - Media OutReach Newswire - 3 July 2025 - AweMed®, a skincare brand developed in collaboration with local dermatologists and paediatricians, sponsored the Eczema Family Day 2025—an annual event organised by Eczema Support Group Singapore (ESGS). The event was held on 12 April, where patients, caregivers, and healthcare professionals came together to share knowledge, foster connections, and support individuals living with eczema in Singapore. Deepening Community Engagement Through Sponsorship The brand's decision to sponsor the Eczema Family Day stems from its ongoing commitment to supporting individuals and engaging local communities with sensitive and eczema-prone skin. While the brand has been providing gentle, eczema-friendly skincare solutions for several years, this marks a new chapter in its efforts to connect directly with the eczema community. 'We've always provided support for eczema patients through our products, but we recognised the need to do more,' said a spokesperson for AweMed®. 'Increasing our visibility within the eczema community has been a long-standing goal. So, when we were approached by the main event organiser about sponsoring or participating in the annual Eczema Family Day, we were eager to get involved.' Awareness and Education on Daily Eczema Management AweMed® also invited Dr. Ellie Choi, a board-certified dermatologist at the National University Hospital, to speak at the event. Her talk, titled 'Eczema Care for All Ages: Managing It in Adults and Kids,' highlighted the chronic nature of eczema and emphasised the importance of consistent, day-to-day management. Dr. Choi also underscored the vital role that eczema support networks play in helping individuals navigate their journey. The brand's involvement also went beyond sponsorship. Team members were present to connect with attendees, offer product samples, and share practical tips on caring for sensitive and eczema-prone skin. A selected number of visitors were offered a free moisturiser for itchy skin, and all ESGS members received a 10% promotional code. Overall, the event provided a meaningful platform for AweMed® to engage directly with the community about their individual skincare concerns. Launch of a New Free Sample Initiative For those who were not present at Eczema Family Day or are not part of the ESGS, AweMed is continuing to offer free samples as part of a three-month initiative. This move is in response to a common concern expressed by many Family Day attendees—hesitation in trying new skincare due to the reactivity of their skin. As such, this initiative is designed to offer a safe, no-obligation way for users to experience the company's formulations firsthand, making its products more accessible to those newly discovering the AweMed® skincare line. This free samples programme is open to all, with no specific eligibility requirements. Samples will be distributed on a first-come, first-served basis while stocks last. Readers can also visit the brand's Instagram page for updates about an ongoing promotion. About AweMed® AweMed® is a Singapore-based skincare brand formulated specifically for sensitive and eczema-prone skin. Developed in collaboration with experienced dermatologists and paediatricians, their range includes targeted solutions such as an eczema spray for quick relief and a skin-sensitive body wash for gentle cleansing. With a commitment to safety, efficacy, and comfort, AweMed empowers individuals to 'Itch Less, Live Better, Feel Awesome.'
